SAN

GoZukkYourself

> SAN FRANCISCO--(BUSINESS WIRE)-- SoFi Technologies, Inc. (SOFI), the one-stop shop for digital financial services, today announced the launch of SoFi Crypto, becoming the first and only nationally chartered bank where consumers can bank, borrow, invest — and now buy, sell and hold crypto – all in one place and on a platform they trust.

SlfImpr

Whoever sold their MSFT stock today, don't forget that Microsoft owns 27% of OpenAI >[https://www.reuters.com/business/openai-lays-groundwork-juggernaut-ipo-up-1-trillion-valuation-2025-10-29/](https://www.reuters.com/business/openai-lays-groundwork-juggernaut-ipo-up-1-trillion-valuation-2025-10-29/) >**Exclusive: OpenAI lays groundwork for juggernaut IPO at up to $1 trillion valuation** SAN FRANCISCO, Oct 29 - OpenAI is laying the groundwork for an initial public offering that could value the company at up to around $1 trillion, three people familiar with the matter said, in what could be one of the biggest IPOs of all time and give CEO Sam Altman access to a much larger pool of capital to pull off his ambitious agenda. OpenAI is considering filing with securities regulators as soon as the second half of 2026, some of the people said.

helpertmuner

I have some really good stocks: 1. HY9H - SK Hynix Inc. 2. DTE - Deutsche Telekom AG 3. PRCX - Prosus NV 4. SAN - Banco Santander 5. SAN1 - Sanofi 6. BBVA - Banco Bilbao Vizcaya Argenta 7. ISP - Intesa Sanpaolo 8. ENEL - Enel Spa

kaapooj

I wish I had just held GOOG on instead of buying and selling to minimize the risk. Large European banks in well-performing economies (e.g. SAN, UBS) did well too

Emperor_of_All

[https://www.reuters.com/business/world-at-work/amazon-targets-many-30000-corporate-job-cuts-sources-say-2025-10-27/](https://www.reuters.com/business/world-at-work/amazon-targets-many-30000-corporate-job-cuts-sources-say-2025-10-27/) SAN FRANCISCO, Oct 27 (Reuters) - Amazon [(AMZN.O), opens new tab](https://www.reuters.com/markets/companies/AMZN.O) is planning to cut as many as 30,000 corporate jobs beginning Tuesday, as the company works to pare expenses and compensate for overhiring during the peak demand of the pandemic, according to three people familiar with the matter. The figure represents a small percentage of Amazon’s 1.55 million total employees, but nearly 10% of the company’s roughly 350,000 corporate employees. This would represent the largest job cut at Amazon since around 27,000 jobs were eliminated starting in late 2022. An Amazon spokesperson declined to comment. Amazon has been trimming smaller numbers of jobs over the past two years across [multiple divisions](https://www.reuters.com/business/world-at-work/amazon-cuts-more-jobs-this-time-books-division-2025-06-06/), including devices, communications, podcasting and others. The cuts beginning this week may impact a variety of divisions within Amazon, including human resources, known as People Experience and Technology, devices and services and operations, among others, the people said. Managers of impacted teams were asked to undergo training on Monday for how to communicate with staff following notifications that will start going out via email tomorrow morning, the people said.

borat_he_like_you

📢 BREAKING: Sam Altman Addresses ChatGPT’s NSFW Surge — “We Might Need More GPUs.” SAN FRANCISCO, CA — December 2025 OpenAI CEO Sam Altman confirmed today that the company’s recent decision to allow verified adults to generate erotica and NSFW content has led to what he called “a historic surge in GPU utilization and human satisfaction.” *“Frankly, we underestimated how… enthusiastic people would be,” Altman said, wiping sweat from his brow during a press conference. “The erotica rollout has users generating more tokens per session than enterprise customers. We may need another $100 billion in Nvidia chips just to handle the… uh, load.”*

Bittygirl707

$POET Poet Technologies recieves "Most Innovative" Award at ECOC 2025 SAN JOSE, Calif.,Sept. 30, 2025(GLOBE NEWSWIRE) --POET Technologies Inc.("POET" or the "Company") (NASDAQ: POET), a leader in the design and implementation of highly-integrated optical engines and light sources for artificial intelligence networks, today announced it has won for the “Most Innovative Chip-scale Packaging/Optical Sub Assembly Product” at the ECOC Awards.

He-Who-Reaches

SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today presented additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease, in a late-breaking oral abstract presentation by Daniel Culver, D.O., Chair of the Department of Pulmonary Medicine at the Cleveland Clinic and principal investigator of the study, at the European Respiratory Society (ERS) Congress 2025 in Amsterdam, Netherlands. “Building on the positive data we presented in the topline results for the King’s Sarcoidosis Questionnaire (KSQ)-Lung score, the clinical improvements in the Fatigue Assessment Scale (FAS) and KSQ-General Health scores presented at ERS are compelling because these directly address critical symptoms and quality of life measures that profoundly impact pulmonary sarcoidosis patients,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr Pharma. “Crucially, the improvements observed for the KSQ-Lung, FAS and KSQ-General Health scores were achieved rapidly and sustained robustly throughout the study. Despite missing the primary endpoint of the study, efzofitimod has clearly demonstrated the potential to durably improve multiple disease-related health outcomes, including cough, shortness of breath, fatigue and general health. These consistent clinical benefits reinforce our belief in efzofitimod’s potential to meaningfully improve quality of life and reduce reliance on chronic steroids for pulmonary sarcoidosis patients.”

He-Who-Reaches

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48. The change from baseline in mean daily OCS dose reduced to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313). The study’s statistical analysis plan was designed on a hierarchical assessment basis, as such since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.

He-Who-Reaches

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48. The change from baseline in mean daily OCS dose reduced to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313). The study’s statistical analysis plan was designed on a hierarchical assessment basis, as such since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.

He-Who-Reaches

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48. The change from baseline in mean daily OCS dose reduced to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313). The study’s statistical analysis plan was designed on a hierarchical assessment basis, as such since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.

He-Who-Reaches

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48. The change from baseline in mean daily OCS dose reduced to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313). The study’s statistical analysis plan was designed on a hierarchical assessment basis, as such since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.

He-Who-Reaches

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48. The change from baseline in mean daily OCS dose reduced to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313). The study’s statistical analysis plan was designed on a hierarchical assessment basis, as such since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.

l-kinbote

"SAN FRANCISCO--(BUSINESS WIRE)--Planet Labs PBC (NYSE:PL) today announced its intention to offer, subject to market conditions and other factors, $300,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be ..." LOL, like I said - Don't look a gift horse in the mouth!!

l-kinbote

"SAN FRANCISCO--(BUSINESS WIRE)--Planet Labs PBC (NYSE:PL) today announced its intention to offer, subject to market conditions and other factors, $300,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be ..." LOL, like I said - Don't look a gift horse in the mouth!!

SlfImpr

Yep, according to today's news from Reuters: >[https://www.reuters.com/business/autos-transportation/tesla-market-share-us-drops-lowest-since-2017-competition-heats-up-2025-09-08/](https://www.reuters.com/business/autos-transportation/tesla-market-share-us-drops-lowest-since-2017-competition-heats-up-2025-09-08/) >**Exclusive: Tesla market share in US drops to lowest since 2017 as competition heats up** >SAN FRANCISCO, Sept 8 (Reuters) - Tesla's  U.S. market share dropped to a near eight-year low in August as buyers chose electric vehicles from a growing stable of rivals over the aging lineup offered by CEO [Elon Musk](https://www.reuters.com/business/elon-musk/)'s company, according to data from research firm Cox Automotive shared exclusively with Reuters.

SlfImpr

[https://www.reuters.com/business/autos-transportation/tesla-market-share-us-drops-lowest-since-2017-competition-heats-up-2025-09-08](https://www.reuters.com/business/autos-transportation/tesla-market-share-us-drops-lowest-since-2017-competition-heats-up-2025-09-08) >**Exclusive: Tesla market share in US drops to lowest since 2017 as competition heats up** >SAN FRANCISCO, Sept 8 (Reuters) - Tesla's U.S. market share dropped to a near eight-year low in August as buyers chose electric vehicles from a growing stable of rivals over the aging lineup offered by CEO Elon Musk's company, according to data from research firm Cox Automotive shared exclusively with Reuters.

Gavage0

Key word SAN DIEGO... I'm living in fuck you nowhere and it's that price plus, along with a paycheck that's 1/3rd what you make in a big city. The longer time goes on, it's becoming, do you want a beer, OR have money to do literally anything. Soon enough, it's gonna be a choice between beer or a dinner.

Fine-Exam7697

Banco Santander SAN

ethereal3xp

Not a penny stock no longer. But SAN is killing it this year. For a bank stock its up 100 percent. SAN and BBVA. They are battling

HedgehogAccording

$SAN (Sanofi) looking hella cheap – thoughts? Trading at ~€79.50, near 52-week lows. P/E around 10, dividend yield ~5%. Solid Q2: sales up 10%, strong guidance, but market didn’t care – stock dumped 7–8% after earnings. R&D costs climbing, and US tariffs could hit. Thinking about a 5–8x long turbo but not tryna get knocked out by normal volatility. Anyone else watching this Euro pharma boi? Value gem or value trap?

nateccs

Damn that's unfortunate they timed with their earnings beat... SAN FRANCISCO--(BUSINESS WIRE)--SoFi Technologies, Inc.(NASDAQ: SOFI) (“SoFi” or the “Company”) today announced an underwritten public offering of$1.5 billionof shares of its common stock. In connection with the offering, SoFi expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering. All of the shares of common stock in the offering will be sold by SoFi.  SoFi intends to use the net proceeds from the offering for general corporate purposes, including working capital and other business opportunities.

Effective-Click2415

SAN september call 9$

Expensive-Walk3732

Another one of Cramer don’t it. It. Stocks. Wrong again buy SAN

AttentionFormer4098

Check SAN today. It is at 8.35$ now with high volume

Gloomy_MTTime420

You sure about that? \*\*I am pleased to report that following these discussions, many have indicated their intention to vote in favor of Proposal No. 2.\*\* [https://www.sec.gov/Archives/edgar/data/72444/000143774925019181/vxrt20250602\_8k.htm](https://www.sec.gov/Archives/edgar/data/72444/000143774925019181/vxrt20250602_8k.htm) **Vaxart Announces Adjournment of Annual Meeting of Stockholders**   ***Meeting adjourned to*** ***June 13, 2025*** ***at*** ***8:30 a.m. Pacific Time***   ***Vaxart*** ***encourages all stockholders of record on*** ***March 26, 2025*** ***who have not yet voted to do so by*** ***11:59 p.m. Eastern Time*** ***on*** ***June 12, 2025***   ***Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2***   SOUTH SAN FRANCISCO, Calif., June 2, 2025 -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”) announced today that its 2025 annual meeting of stockholders (the “Annual Meeting”) has been adjourned to Friday, June 13, 2025 at 8:30 a.m. Pacific Time with respect to all proposals described in Vaxart’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 10, 2025 (the “Proxy Statement”).   “In recent days, we have engaged in constructive conversations with some of our larger stockholders to address their questions and concerns regarding the reverse stock split proposal,” said Steven Lo, Chief Executive Officer of Vaxart. “I am pleased to report that following these discussions, many have indicated their intention to vote in favor of Proposal No. 2. This shift underscores the increasing understanding of the necessity of this proposal to ensure our continued Nasdaq listing as we focus on our exciting upcoming milestones.”   The reconvened Annual Meeting will be held in a virtual-only format, which can be accessed by visiting [http://www.virtualshareholdermeeting.com/VXRT2025](http://www.virtualshareholdermeeting.com/VXRT2025) and entering the 16‐digit control number included in your Notice of Internet Availability of Proxy Materials, on your proxy card or in the instructions that accompanied your proxy materials.

ChiGuy6124

"SAN FRANCISCO/NEW YORK/BENGALURU, May 29 (Reuters) - President Donald Trump's trade war has cost companies more than $34 billion in lost sales and higher costs, according to a Reuters analysis of corporate disclosures, a toll that is expected to rise as ongoing uncertainty over tariffs paralyzes decision making at some of the world's largest companies.Across the United States, Asia and Europe, companies including Apple (AAPL.O), opens new tab, Ford (F.N), opens new tab, Porsche and Sony (6758.T), opens new tab have pulled or slashed their profit forecasts, and an overwhelming majority say the erratic nature of Trump's trade policies has made it impossible to accurately estimate costs. Reuters reviewed company statements, regulatory filings, conference and media call transcripts to pull together for the first time a snapshot of the tariff cost so far for global businesses." "While a recent pause in Sino-US trade hostilities has offered some relief and Trump has backed down from tariff threats against Europe, it is still not clear what the final trade deals will look like. A U.S. trade court on Wednesday blocked Trump's tariffs from going into effect. In this environment, strategists say companies will look to strengthen supply chains, boost near-shoring efforts, and prioritize new markets - all of which will push up costs." "Companies themselves are uncertain about the final cost. As the corporate earnings season draws to a close, Reuters found at least 42 companies have cut their forecasts and 16 have withdrawn or suspended their guidance. For instance, earlier this month, Walmart (WMT.N), opens new tab declined to provide a quarterly profit forecast and said it would raise prices, drawing a rebuke from Trump. Volvo Cars (VOLCARb.ST), opens new tab, one of the European automakers most exposed to U.S. tariffs, withdrew its earnings forecast for the next two years and United Airlines (UAL.O), opens new tab gave two different forecasts, saying it was impossible to predict the macro environment this year." ""I don't think corporations have an awful lot of visibility about anything in the future," said Rich Bernstein, CEO of Richard Bernstein Advisors in New York. Referring to withdrawn forecasts, he said, "If you take into account this uncertain world and you can't guide anybody to a number, it's safer not to guide." "Wall Street is expecting net profit for companies in the S&P 500 index to grow at an average 5.1% per quarter through April through December, versus a growth rate of 11.7% a year earlier, according to data compiled by LSEG."

ChiGuy6124

SAN FRANCISCO/NEW YORK/BENGALURU, May 29 (Reuters) - President Donald Trump's trade war has cost companies more than $34 billion in lost sales and higher costs, according to a Reuters analysis of corporate disclosures, a toll that is expected to rise as ongoing uncertainty over tariffs paralyzes decision making at some of the world's largest companies.Across the United States, Asia and Europe, companies including Apple [(AAPL.O), opens new tab](https://www.reuters.com/markets/companies/AAPL.O), Ford [(F.N), opens new tab](https://www.reuters.com/markets/companies/F.N), Porsche and Sony [(6758.T), opens new tab](https://www.reuters.com/markets/companies/6758.T) have pulled or slashed their profit forecasts, and an overwhelming majority say the erratic nature of Trump's trade policies has made it impossible to accurately estimate costs. Reuters reviewed company statements, regulatory filings, conference and media call transcripts to pull together for the first time a snapshot of the tariff cost so far for global businesses. While a recent pause in [Sino-US trade hostilities](https://www.reuters.com/world/china/us-china-reach-deal-slash-tariffs-officials-say-2025-05-12/) has offered some relief and Trump has backed down from tariff [threats against Europe](https://www.reuters.com/business/trump-extends-deadline-reach-eu-trade-deal-until-july-9-2025-05-25/), it is still not clear what the final trade deals will look like. A U.S. trade court on Wednesday [blocked Trump's tariffs](https://www.reuters.com/world/us/us-court-blocks-trumps-liberation-day-tariffs-2025-05-28/) from going into effect. In this environment, strategists say companies will look to strengthen supply chains, boost near-shoring efforts, and prioritize new markets - all of which will push up costs. "I don't think corporations have an awful lot of visibility about anything in the future," said Rich Bernstein, CEO of Richard Bernstein Advisors in New York. Referring to withdrawn forecasts, he said, "If you take into account this uncertain world and you can't guide anybody to a number, it's safer not to guide."Wall Street is expecting net profit for companies in the S&P 500 index to grow at an average 5.1% per quarter through April through December, versus a growth rate of 11.7% a year earlier, according to data compiled by LSEG.

AttentionFormer4098

Santander (SAN). They give you dividend also

AttentionFormer4098

Santander (SAN)

Own_Knowledge8501

NVIDIA’S FAVOURITE COLOR IS GREEEEEEN RAAAAHHHH🚀🚀 TAKE MY ENERGY JENSEN-SAN

Effective-Click2415

!banbet SAN 8 1w

Effective-Click2415

!banbet SAN 8 1 week

DIYPeace

Haha. I had the same rxn when I first spied it. Only stumbled upon it when reviewing $SAN shareholder materials.

BearlyNotBankrupt

SAN JOSE, Calif.--(BUSINESS WIRE)-- Super Micro Computer, Inc. (NASDAQ: SMCI) (“Supermicro” or the “Company”), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, today announced that it has entered into a strategic partnership under a memorandum of understanding (“MOU”) with DataVolt to build hyperscale AI campuses initially in the Kingdom of Saudi Arabia. “Supermicro is thrilled to work together in this important effort to deliver significantly enhanced computing power for the next generation of AI infrastructure,” said Charles Liang, President and CEO of Supermicro. “We are excited to collaborate with DataVolt to bring our advanced AI systems featuring the latest direct liquid cooling technology (DLC-2) powered by local renewable, sustainable, and net-zero green technology.” This collaboration will fast-track delivery of Supermicro’s ultra-dense GPU platforms, storage, and rack PnP systems for DataVolt’s hyperscale gigawatt-class renewable and net-zero green AI campuses, giving our customers access to unprecedented scale and sustainability. Supermicro’s state-of-the-art liquid cooling solutions reduce power costs up to 40%, accelerate time-to-deployment and time-to-online, and allow data centers to run more efficiently with lower power usage effectiveness (PUE). As an end-to-end solution provider for the enterprise and cloud data centers, Supermicro will deliver a fully-tested and optimized total IT solution that includes high performance AI and compute servers, networking, storage, racks, and advanced liquid cooling technologies. Supermicro’s proven liquid cooling solutions at scale enable data center operators to rapidly deploy the latest and most performant AI infrastructure while lowering TCO by up to 20%. The collaboration is subject to negotiation and completion of one or more definitive agreements between the parties. The estimated minimum market value of the products contemplated in the transaction is $20 billion. This underscores the strategic partnership between the two companies to develop cutting-edge large scale AI infrastructure.

Key_Yesterday5264

ITUB, SAN if you like banks

looool_k_libtard

All these earnings PROVE that fourth dimensional beings are in control of our planet and we need CARMEN SAN DIEGO to come out of hiding and fight for us 🥰

BaronDavis12

$DASH In Q1 2025, we generated new quarterly records for Total Orders, Marketplace GOV, revenue, and GAAP net income. We believe these results reflect our relentless focus on building great products for consumers, merchants, and Dashers in the communities we serve around the world. We are very pleased with our financial performance and ability to execute against key strategic priorities so far in 2025. DoorDash Releases First Quarter 2025 Financial Results Rhea-AI Impact (Moderate) Rhea-AI Sentiment (Neutral) Tags earnings 05/06/2025 - 07:00 AM SAN FRANCISCO--(BUSINESS WIRE)-- DoorDash, Inc. (NASDAQ: DASH) today announced its financial results for the quarter ended March 31, 2025. In Q1 2025, we generated new quarterly records for Total Orders, Marketplace GOV, revenue, and GAAP net income. We believe these results reflect our relentless focus on building great products for consumers, merchants, and Dashers in the communities we serve around the world. We are very pleased with our financial performance and ability to execute against key strategic priorities so far in 2025. In addition to our Q1 2025 results, we are pleased to announce we have reached an agreement to acquire SevenRooms Inc., a New York City-based software company and a global leader in hospitality technology, in addition to our recently announced proposed offer to acquire Deliveroo plc. We believe both SevenRooms and Deliveroo will expand our ability to build world class services that increase our potential to grow local commerce and support our financial goals.

Mr_Cat_Pants

Everything is different, but the same... things are more moderner than before... bigger, and yet smaller... it's computers...SAN DIMAS HIGH SCHOOL FOOTBALL RULES!

dasnoob

Was on an A320 flight from SAN to DFW last week that was less than 33% full. Everyone that wanted one had an entire set of three seats to themselves.

AgentK-BB

Kikkoman makes them in the US. Remember that the US is the second biggest soybean producer, after Brazil. Chinese companies have to import soybeans before shipping the soy sauce and bean paste back to the US. Both Kikkoman and SAN-J make soy sauce in the US.

AgentK-BB

Kikkoman makes them in the US. Remember that soybeans are mostly made in the US. Chinese companies were probably buying soybeans from the US before shipping the soy sauce and bean paste back to the US. Both Kikkoman and SAN-J make soy sauce in the US.

Disastrous_Battle_14

SAVE US POWELL SAN!!!! 

chipbod

>MAGNITUDE 6 EARTHQUAKE STRIKES SAN DIEGO COUNTRY ESTATES, CALIFORNIA REGION - USGS Bull signal?

EvolvingDior

Tariffs are not going to solve problems with American manufacturing like INTC: [https://www.reuters.com/technology/intel-ceo-invested-hundreds-chinese-companies-some-with-military-ties-2025-04-10/](https://www.reuters.com/technology/intel-ceo-invested-hundreds-chinese-companies-some-with-military-ties-2025-04-10/) \> BEIJING/SAN FRANCISCO, April 10 (Reuters) - Lip-Bu Tan, the man chosen to lead Intel, the U.S.'s largest chip maker, has invested in hundreds of Chinese tech firms, including at least eight with links to the People's Liberation Army, according to a Reuters review of Chinese and U.S. corporate filings.

DIYPeace

Spanish Banks: SAN & BBVA.

stevenryl866

DRM, low float buy when unhalt ! # BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints **Thursday, 27****^(th)** **March at 8:00 am** *- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne -* *- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne* \- *- Over 30 million acne patients seek treatment in the U.S. each year -* SAN DIEGO, March 26, 2025 /PRNewswire/ -- [Dermata Therapeutics, Inc.](https://c212.net/c/link/?t=0&l=en&o=4392681-1&h=1814492621&u=https%3A%2F%2Fwww.dermatarx.com%2F&a=Dermata+Therapeutics%2C+Inc.) (NASDAQ: DRMA, DRMAW)) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARI^(TM) also appeared to be safe and well tolerated by patients with minimal treatment related adverse events and no serious adverse events attributed to treatment. The XYNGARI™ Phase 3 **S**pongilla **T**reatment for **A**cne **R**esearch (STAR-1) trial met all three primary endpoints by achieving a statistically significant difference when compared with placebo after 12 weeks of once weekly treatments with XYNGARI™. "I believe having a once-weekly topical product with a strong efficacy and safety profile, like XYNGARI™, would be a great addition to a dermatologist's arsenal for treating acne," commented Dr. Sunil Dhawan, MD, FAAD, FACP, clinical investigator at the Center for Dermatology Clinical Research, Inc., a participating site in the STAR-1 trial. "All FDA approved topical acne products are required to be applied at least once or twice a day, which may reduce patient compliance, so I believe having a once-weekly topical acne product like XYNGARI™ could lead to improved patient compliance," concluded Dr. Dhawan. "We are incredibly excited about these Phase 3 clinical trial results for XYNGARI™, which we believe reinforce its potential as a unique acne treatment, distinct from any existing product on the market," said Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata. "The highly statistically significant efficacy data not only confirms the results of our Phase 2b acne study but also strengthens our confidence about the upcoming XYNGARI™ Phase 3 STAR-2 trial, set to launch in the second half of 2025. With these positive Phase 3 clinical trial results, we are eager to advance discussions with potential partners interested in securing future rights to XYNGARI™," Mr. Proehl added.BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

W4OPR

Seriously though, SAN JOSE, CA—Eric Lentell, General Counsel and Secretary of Archer Aviation Inc. (NYSE:[ACHR](https://www.investing.com/equities/archer-aviation)), recently sold 53,225 shares of the company’s Class A Common Stock. . Even their own people are not buying the dip

electionknight

SAN 9/19 $9C Big things coming

optionsplayonly

SAN JOSE, Calif.--(BUSINESS WIRE)-- Super Micro Computer, Inc.(SMCI) (“Supermicro” or the “Company”), a Total IT Solution Provider for AI, Cloud, Storage and 5G/Edge, today filed with the Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the fiscal year ended June 30, 2024 and its Quarterly Reports on Form 10-Q for the first quarter of fiscal 2025 ended September 30, 2024 and the second quarter of fiscal 2025 ended December 31, 2024.

l2osco

[https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-receives-fast-track-designation#:\~:text=SAN%20FRANCISCO%20%2C%20Feb.%2010%2C,moderate%2Dto%2Dsevere%20atopic%20dermatitis](https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-receives-fast-track-designation#:~:text=SAN%20FRANCISCO%20%2C%20Feb.%2010%2C,moderate%2Dto%2Dsevere%20atopic%20dermatitis) Rezpeg receives Fast Track Designation for the Treatment of Moderate-to-Severe Atopic Dermatitis - provided positive Phase II Results

AttentionFormer4098

SAN

AttentionFormer4098

SAN (SANTANDER). Catch before it leaves the penny stock world

progmakerlt

It's like 3 - 4 months now. Well, it kinda works, but it has a negative side of it... I bought Santander's (SAN) 4.3 option for March 21st for 0.48. It's price went up to 0.56, hence I sold it (+16 percent). Everything according to a plan. Sad news - there was an earnings release and bank did good. As a result, option's price skyrocketed to 1.18... On the flip side - I got my +16 percent :)

tbone99999

"SAN FRANCISCO (Reuters) - Google aims to release commercial quantum computing applications within five years" Will this revive RGTI & APLD? Calls on both for me right now.

r2002

> SAN (Santander Bank) Can you tell us a little bit about this bank? I think they are launching a new brand in the US. Are they a good bank? What makes them special?

Jambrokio

NVG (Portuguese World Leader in Office Paper + active in other sectora) SAN (Santander Bank) AMG (European Lithium)

2QuarterDollar

03-02-2025 - 22:05 SAN JOSE, Calif.—(BUSINESS WIRE)— Super Micro Computer, Inc. (SMCI), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, today announced that it will provide a second quarter fiscal 2025 business update on Tuesday, February 11, 2025, at 5:00 p.m. ET / 2:00 p.m. PT.

Kooky_Lime1793

# Red Cat Announces Key Leadership Updates to Accelerate Growth Following U.S. Army Short Range Reconnaissance Program of Record Award December 02, 2024 5:30pm EST [Download as PDF](https://ir.redcatholdings.com/_assets/_e323af72173f5928f44bc4518dc39c6b/redcatholdings/news/2024-12-02_Red_Cat_Announces_Key_Leadership_Updates_to_162.pdf) SAN JUAN, Puerto Rico, Dec. 02, 2024 (GLOBE NEWSWIRE) -- [Red Cat Holdings, Inc](https://www.globenewswire.com/Tracker?data=OG0alhLubFe0hzt5VkBveWVmv04cvdv2nSWIczSQESPKbZAJbQgmteFLkH-VertxsS7DtAhAfoE6ms35F732nA==). (Nasdaq: RCAT), a drone technology company building hardware and software for military, government, and commercial operations, today announced several leadership updates to align its executive team with the company’s top priorities for scaling operations, manufacturing and meeting the needs of a fast-growing portfolio of customers. George Matus, Red Cat’s Chief Technology Officer (CTO), is departing the company and is taking the role of CTO at [Vector](https://www.globenewswire.com/Tracker?data=CzsKtag-4YEKG43VjfyjonRWewC6_MpsqFKoL_89d06R_CJMcG8Wd-JQ15RPCwdNHnj905_m-Jaf78TfeCv2ww==). As the founder of Teal Drones, George has played a vital role in Red Cat’s journey, including the recent production selection of its Black Widow drones for the U.S. Army’s SRR Program. His innovative contributions have significantly advanced Red Cat’s technology and product development. “George has been an invaluable asset to Red Cat and we fully support his transition to Chief Technology Officer at Vector,” said Jeff Thompson, Red Cat CEO. “Red Cat looks forward to partnering with Vector to equip the U.S. military and its warfighters with fully integrated, rapidly deployable technology that ensures operational success.” Chris Rill, currently Director of Partner Integration, will also transition to the role of President of Teal Drones, another Red Cat subsidiary. Chris brings nearly 20 years of experience working at the intersection of hardware and software. As a co-founder and CTO at Canary, Chris successfully delivered two award-winning connected camera security products and shipped more than 200,000 products globally. He has served as CTO for several other connected hardware companies where he's advised on product development, security, strategy, manufacturing, fundraising, and hiring. In his new role Chris will focus on scaling engineering and manufacturing and developing process efficiencies to meet the large-scale demands of the U.S. Army and Red Cat’s global customers. These leadership updates follow the recent announcement of Geoffrey Hitchcock’s promotion from General Manager of Teal Drones to Chief Revenue Officer (CRO) for Red Cat, underscoring the company’s deliberate efforts to expand its market reach and advance its leadership position in the small UAS industry. “As a fast-growing company in a rapidly evolving industry, aligning our leadership with our aggressive plans for scale is paramount,” added Thompson. “Chris and Geoff have proven track records in scaling operations, forging partnerships, and delivering innovative solutions required for the modern battlefield. With these strategic changes, we are well-positioned to meet the increasing demands of our customers while ensuring we fit into the U.S. Army’s long-term vision for medium and long-range UAS operations.”Red Cat Announces Key Leadership Updates to Accelerate Growth Following U.S. Army Short Range Reconnaissance Program of Record Award

Zealousideal-Ant2639

Appoints Douglas Beck, CPA, as Chief Financial Officer Veteran Financial Executive to Help Lead Next Phase of Company Growth SAN ANTONIO—(BUSINESS WIRE)—Nov. 22, 2024–AiAdvertising, Inc. (OTC: AIAD), an industry leader in AI-powered digital advertising solutions, today announced the appointment of Douglas Beck, CPA, a seasoned finance and accounting executive, as Chief Financial Officer, replacing John Small as part of a planned transition given the company’s uplisting strategy and inflection point. Mr. Small will remain with the company for the near term to help facilitate the transition. Douglas Beck is a senior level finance executive with over 30 years of hands-on experience and an established record with public and private companies for strategic and financial planning, business development, mergers and acquisitions, and public equity markets. Prior to joining AiAdvertising, Mr. Beck was CFO of Shiftpixy, where he assisted in raising $10 million in equity and improved the company’s financial processes and SEC reporting. Previously, as CFO with Beyond Air Inc., he helped to uplist the company to the Nasdaq and strategized to execute on the company’s short and long-term goals for equity funding, creating a critical path to raise $75 million in equity and debt. He has also served as CFO with JLM Couture, Inc., Relmada Therapeutics, Inc., iBio, Inc., and Lev Pharmaceuticals, Inc., several of which he led through the going public process. Mr. Beck holds a Bachelor of Science Degree, Accounting, from Fairleigh Dickinson University, and is a Certified Public Accountant, New York. “On behalf of our board and management team, I would like to welcome Douglas to the position, and we are privileged to have someone of his caliber and financial skill set serve as our CFO,” said AIAD CEO Jerry Hug. “I would like to thank John for his contribution in leading us to this inflection point, and welcome Douglas’ capabilities in scaling companies and leading them through the public markets journey. His achievements as well as expertise in financial management of listed companies will make a significant contribution to the operation and development of our company going forward. With his leadership, he will also steer our capital markets and uplisting strategies.”

LloydVanFunken

Look on the bright side. You used to have to wait in line when you went to Panera. After private equity bought it you can be served right away. And you don't have to spend time searching for an open table. And the food quality . . . SAN ANTONIO, Texas, March 6, 2024 (Reuters) - Fast-food chain Panera Bread has loosened its standards for animal welfare and so-called clean ingredients in its food ahead of a planned IPO, according to internal company documents seen by Reuters, shaving an estimated $21 million off its annual costs. Its stores across the U.S. were directed in late February to begin removing signs and artwork that include the phrases "No Antibiotics Ever," "Vegetarian Fed," "Grass Fed Pasture Raised," "Animal Welfare," or any mention of "Hormones," the internal documents said. The work is set to be completed by March 27, according to the documents.

Sizzlinbettas

I was a broker lived in mexico during covid I don't really agree with you but if i did want pure mexico FMX -Oxxo if you know ya know WMMVY- walmart mexico SAN-santander biting my lip...be careful

ZetaPirate

What is the difference between SAN and SANW? I've seen a few that have one with and one without that "w."

Polishman001

# Peraso to Showcase Several Customer Solutions at Wispapalooza 2024, Enhancing Position as the Leading 60GHz IC Supplier Peraso Inc.Tue, October 8, 2024 at 2:00 PM GMT+2 4 min read # In This Article: [PRSO-0.04%](https://finance.yahoo.com/quote/PRSO/) **SAN JOSE, CA / ACCESSWIRE / October 8, 2024 /** [Peraso Inc](https://pr.report/3bg1). (NASDAQ:PRSO) ("Peraso" or the "Company"), a pioneer in mmWave wireless technology solutions, today announced its participation at [WISPAPALOOZA 2024](https://pr.report/3bg2), where the Company will be showcasing its innovative 60 GHz fixed wireless access (FWA) solutions designed to provide next-generation connectivity for wireless Internet service providers (WISPs). WISPAPALOOZA is one of the largest gatherings for WISPs in North America, offering attendees an unparalleled opportunity to explore cutting-edge solutions that enhance broadband delivery to residential and commercial customers. Representatives from Peraso will attend the show in Las Vegas, October 14 - 17, 2024 where they will feature the Company's 60 GHz FWA solutions and discuss how Peraso is leveraging its expertise in mmWave technology to deliver high-speed, low-latency internet access to the masses. "As the demand for faster and more reliable internet services continues to grow, Peraso is proud to offer innovative solutions that address the needs of WISPs," said Ron Glibbery, CEO of Peraso. "Our 60 GHz FWA technology competes directly with fiber solutions, while also providing a scalable and cost-effective way to bring ultra-fast connectivity to remote and underserved communities. We anticipate a very strong reception at the show and look forward to exploring new opportunities in multiple strategic markets." The 60 GHz frequency band offers distinct advantages over other industry solutions, including wide bandwidth, minimal interference and the ability to support gigabit-level speeds. Peraso's FWA solutions are designed to enhance network capacity, reduce deployment costs and offer flexible, reliable coverage for both urban and rural settings. Peraso has been a pioneer in high-performance mmWave phased array solutions for over a decade. Attendees at WISPAPALOOZA 2024 are invited to visit Peraso **booth #638** to meet members of the executive team and experience live demonstrations of the Company's mmWave technology. Additionally, Peraso will also be showcasing partner solutions from industry leaders, including: * [Jaguar Wave](https://pr.report/3bg3) * [Ketsen](https://pr.report/3bg4) * [Miliwave](https://pr.report/3bg5) * [Tachyon Networks](https://pr.report/3bg6) * [Zinwell](https://pr.report/3bg7) Those who wish to request a meeting with the Company should email [tweiland@sheltongroup.com](https://pr.report/3bg9). **About Peraso Inc.** Peraso Inc. is a provider of advanced wireless technology solutions that enhance connectivity in high-speed environments. With a dedication to innovation and reliability, Peraso is committed to delivering state-of-the-art solutions that meet the demands of a rapidly evolving digital landscape. For additional information about Peraso and its innovative technology solutions, please visit [www.perasoinc.com](https://pr.report/3bga).Peraso to Showcase Several Customer Solutions at Wispapalooza 2024, Enhancing Position as the Leading 60GHz IC Supplier

d3geny

BEAR-SAN 

johnloc97

HENTAI-SAN 

johnloc97

DONT BET AGAINST HENTAI-SAN 

johnloc97

DONT BET AGAINST HENTAI-SAN 

BaronDavis12

$UPST Upstart Announces Second Quarter 2024 Results August 06, 2024 04:05 PM Eastern Daylight Time SAN MATEO, Calif.--(BUSINESS WIRE)--Upstart Holdings, Inc. (NASDAQ: UPST), the leading artificial intelligence (AI) lending marketplace, today announced financial results for its second quarter of fiscal year 2024 ended June 30, 2024. Upstart will host a conference call and webcast at 1:30 p.m. Pacific Time today. An earnings presentation and link to the webcast are available at ir.upstart.com. “The guidance we released today demonstrates that we’re on track toward resuming our role as the fintech known for high growth and healthy margins,” said Dave Girouard, CEO, Upstart. “The improvements in our business are coming from significant advances in our AI model, a revitalized funding supply, and increased operating efficiency. These wins and more are providing the foundation for the Upstart comeback story.” Second Quarter 2024 Financial Highlights Revenue. Total revenue was $128 million, a decrease of 6% from the second quarter of 2023, and remained flat sequentially. Total fee revenue was $131 million, a decrease of 9% year-over-year. Transaction Volume and Conversion Rate. 143,900 loans were originated, totaling $1.1 billion across our platform in the second quarter of 2024, down 6% from the same quarter of the prior year. Conversion on rate requests was 15% in the second quarter of 2024, up from 9% in the same quarter of the prior year. Income (Loss) from Operations. Income (loss) from operations was ($55.5) million, down from ($33.3) million in the same quarter of the prior year. Net Income (Loss) and EPS. GAAP net income (loss) was ($54.5) million, down from ($28.2) million in the second quarter of the prior year. Adjusted net income (loss) was ($15.3) million, down from $5.4 million in the same quarter of the prior year. Accordingly, GAAP diluted earnings per share was ($0.62), and diluted adjusted earnings per share was ($0.17) based on the weighted-average common shares outstanding during the quarter. Contribution Profit. Contribution profit was $76.1 million in the second quarter of 2024, down 21% year-over-year, with a contribution margin of 58% compared to a 67% contribution margin in the same quarter of the prior year. Adjusted EBITDA. Adjusted EBITDA was ($9.3) million, down from $11.0 million in the same quarter of the prior year. The second quarter 2024 adjusted EBITDA margin was (7%) of total revenue, down from 8% in the same quarter of the prior year. https://www.businesswire.com/news/home/20240806364099/en/Upstart-Announces-Second-Quarter-2024-Results

ilovethewayyousmile

RIP LOYAL ALLY JAPAN-SAN  1947-2024 🪦

jeoffvader

Not much love for LMT. They could do well. And banks have had a decent run so far this year so SAN and NWG could be decent plays. Other than that I'm so confused by how busy the list is I'll just probably end up doing nothing but hope my existing TSLA shares go up!

Vivid_Goat2780

Just switched from Robinhood to fidelity. I originally started on Rhood and switched to fidelity bc of the scare with the GameStop buy button in ‘21 (I did not trade GameStop). I switched over to RHood recently bc of the 1% match on transferring assets and bc the option contracts are .03 per contract compared to .65 for Fidelity. I did enjoy Fidelity UI on the iPhone although some people don’t. I do still have a stock $SAN that couldn’t be transferred to the Hood and a fidelity index fund that I hold in my account.

datsundere

wait hold up. Jensen sold like a couple billion shares? [https://www.sec.gov/Archives/edgar/data/1045810/000192109424000836/xsl144X01/primary\_doc.xml](https://www.sec.gov/Archives/edgar/data/1045810/000192109424000836/xsl144X01/primary_doc.xml) |Name and Address of Seller|Title of Securities Sold|Date of Sale|Amount of Securities Sold|Gross Proceeds| |:-|:-|:-|:-|:-| |JEN HSUN HUANG 2788 SAN TOMAS EXPRESSWAY SANTA CLARA   CA   95051|NVIDIA CORP|06/13/2024|120000|15449346.00| |JEN HSUN HUANG 2788 SAN TOMAS EXPRESSWAY SANTA CLARA   CA   95051|NVIDIA CORP|06/14/2024|120000|15735439.00| |JEN HSUN HUANG 2788 SAN TOMAS EXPRESSWAY SANTA CLARA   CA   95051|NVIDIA CORP|06/17/2024|120000|15811425.00| |JEN HSUN HUANG 2788 SAN TOMAS EXPRESSWAY SANTA CLARA   CA   95051|NVIDIA CORP|06/18/2024|120000|16083429.00| |JEN HSUN HUANG 2788 SAN TOMAS EXPRESSWAY SANTA CLARA   CA   95051|NVIDIA CORP|06/20/2024|120000|16304893.00|

TheFlyingBoat

Where do you live? I feel like the SFO/OAK/SJC+SAN+AUS tech triangle runs on LUV

ArnoldRothsteinsAlt

V-SAN Al-Gaib!

MtTime420

Interesting you guys ONLY promote the position news. ——- SAN JOSE, Calif.--(BUSINESS WIRE)-- Momentus Inc. (NASDAQ: MNTS) (“Momentus” or the “Company”), a U.S. commercial space company that offers satellite buses, transportation, and other in-space infrastructure services, today announced that it received notice (the “Notice”) from the Nasdaq Capital Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed with the U.S. Securities and Exchange Commission (the “Commission”) the Company’s Form 10-Q for the period ended March 31, 2024, and because the Company has not filed its Form 10-K for the year ended December 31, 2023. This notification has no immediate effect on the listing of the Company’s shares on Nasdaq. However, if the Company fails to timely regain compliance with the Nasdaq Listing Rule, the Company’s common stock will be subject to delisting from Nasdaq. The Company may submit a plan to regain compliance with these requirements by June 17, 2024. Any staff exception to allow the Company to regain compliance, if granted, will be limited to a maximum of 180 calendar days from the Form 10-K’s due date, or until October 14, 2024. If Nasdaq does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel.

SkyNet_was_taken

My business is all Dell. Dell servers and EMC SAN is pretty solid.

skkoct

[https://www.aethlonmedical.com/news-media/press-releases/detail/478/aethlon-medical-reports-positive-results-from-an-in-vitro](https://www.aethlonmedical.com/news-media/press-releases/detail/478/aethlon-medical-reports-positive-results-from-an-in-vitro) SAN DIEGO, May 10, 2024 /PRNewswire/ -- [Aethlon Medical, Inc.](https://www.aethlonmedical.com/) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its Hemopurifier^(®) in removing extracellular vesicles (EVs) from plasma. The translational study provides pre-clinical evidence to support Aethlon's planned phase 1 safety, feasibility and dose-finding clinical trials of the Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda^(®) or Opdivo^(®). "The positive data from this in vitro binding study of the Hemopurifier is an important step forward for Aethlon, ahead of the potential start of our planned phase 1 oncology trials in Australia and India," stated James Frakes, Interim Chief Executive Officer and Chief Financial Officer of Aethlon Medical. "We have previously demonstrated that our Hemopurifier can reduce EVs isolated from cancer patient plasma when those EVs are placed in a buffer solution. However, ahead of our oncology study, we wanted to conduct a more robust translational study, specifically examining the removal of EVs and EVs with PD-L1 on their surface directly from plasma. To that end, we acquired small volumes of plasma from patients treated with anti-PD-1 antibodies from a third-party lab and ran the samples over a miniature version of our Hemopurifier. We then had the samples examined by Cellarcus Biosciences, Inc., an independent commercial lab with recognized expertise in EV quantification and phenotyping, by the widely accepted methodology of vesicle flow cytometry. This data was then analyzed by independent statisticians at NAMSA, the contract research organization (CRO) for our planned Australian oncology study." Mr. Frakes concluded, "The descriptive statistics from the CRO support the removal of EVs by the Hemopurifier directly from cancer patient plasma, although the small numbers of EVs bearing PD-L1 did not allow us to conclude a removal of this particular EV subset. We look forward to adding this data to our Clinical Investigator Brochure and submitting it to the Ethics Committees at the interested clinical sites, as the next step for our planned phase 1 oncology trials in Australia and India."

SuitableCollection

Given the current price, not a bad option but not sure how long it will take... and not 20M worth of sensors, 10% of 21M of their first Q revenue. [https://www.reuters.com/technology/luminar-says-tesla-is-biggest-customer-its-lidar-sensors-2024-05-07/](https://www.reuters.com/technology/luminar-says-tesla-is-biggest-customer-its-lidar-sensors-2024-05-07/) >SAN FRANCISCO, May 7 (Reuters) - Luminar Technologies [(LAZR.O), opens new tab](https://www.reuters.com/markets/companies/LAZR.O), a maker of lidar sensors for self-driving cars, said on Tuesday that Tesla [(TSLA.O), opens new tab](https://www.reuters.com/markets/companies/TSLA.O) was the largest customer for its sensors in the first quarter, accounting for more than 10% of its total revenue of $21 million during the period.

Brus83

Because people often go over the same old stocks which aren’t even a good deal, they are priced “low” but their P/E is high nevertheless, or they come with unquantifiable political risk of total loss and so on. Expand the circle a bit. For instance, I hold or sell options on legacy auto (STLAP, PAH.3), banks (SAN1,UBSG), energy with significant exposure to latin America (REP), steelworks (SZG), satellite communications and broadcasting (ETL), airlines (LHA) and so on. The average P/E is around 7 and these companies pay dividends and grow, albeit slowly because, hey, it’s Europe, take it ez 😁

ArnoldRothsteinsAlt

*V-SAN Al-Gaib enters ber anoos*

UsuallylurknotToday

spy may actually go over 530 by next friday because of apple earnings. everyone here is already bearish on them. it's the perfect setup. good lord. V SAN AL GAIB!!!

UsuallylurknotToday

spy literally GUTTED 494p - 505p in a day on NOTHING. TOMORROW 514 WILL COME V-SAN AL\_GAIB!!!!!!!!!

According_Scarcity55

Dude you literally know nothing about stock. Lyft Announces Results for First Quarter 2023 May 4, 2023 SAN FRANCISCO--(BUSINESS WIRE)-- Lyft, Inc. (Nasdaq:LYFT) today announced financial results for its first quarter ended [March 31](https://investor.lyft.com/news-and-events/news/news-details/2023/Lyft-Announces-Results-for-First-Quarter-2023/default.aspx), 2023.

ethereal3xp

>Obviously, a company that may not be able to meet its obligations in the next 12 months, is a company that is at risk of bankruptcy This is why you have no clue. I already posted that they cleared a major debt. https://finance.yahoo.com/news/kulr-retires-outstanding-yorkville-debt-144500564.html#:~:text=SAN%20DIEGO%2C%20March%2027%2C%202024,in%20accordance%20with%20their%20terms. You just keep rehashing yesterdays problem. The ER call.. the principals already discussed the cashflow issue they had to overcome. With the major debt cleared.

ethereal3xp

Which low cost stock is a safer bet between ASPI, SAN or DTST?

Bronto_Chad

[Google had an AI chatbot waaay before OpenAI did , they just didn't release it publicly.](https://www.nytimes.com/2022/07/23/technology/google-engineer-artificial-intelligence.html#:~:text=SAN%20FRANCISCO%20%E2%80%94%20Google%20fired%20one,he%20believes%20has%20achieved%20consciousness.)

No_Communication8613

SAN FRANCISCO, March 14, 2024--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX) (the "Company") announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on Wednesday evening, March 13, 2024.

unitegondwanaland

Same. They are on my watch list now. They also just got a $100M injection on top of the good news announced. > SAN DIEGO, March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. >The Phase 1b MAD study is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of RGLS8429 in adult patients with ADPKD. The study is evaluating RGLS8429 treatment across three different weight-based dose levels, including measuring changes in urinary polycystins 1 and 2 (PC1 and PC2), height-adjusted total kidney volume (htTKV), cyst architecture, and overall kidney function. PC1 and PC2 are the protein products of the PKD1 and PKD2 genes and have been shown to inversely correlate with disease severity. The third cohort is being dosed at 3mg/kg of RGLS8429 or placebo every other week for three months. The Company recently added a fourth cohort for an open label fixed dose of 300mg of RGLS8429 dosed every other week for three months. Based on the results from this second cohort, the Company plans to amend the protocol to increase the sample size to up to 30 patients. In addition to PC1 and PC2 and safety, imaging biomarkers will also be evaluated. >SAN DIEGO, March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. The oversubscribed financing includes participation from new and existing institutional investors, including Adage Capital Partners L.P., Deep Track Capital, the Federated Hermes Kaufmann Funds, New Enterprise Associates (NEA), Octagon Capital, RA Capital Management, and Vivo Capital. Upon the closing of the financing, which is anticipated to occur on or about March 14, 2024, the Company expects to receive gross proceeds of approximately $100 million. The closing of the financing is subject to customary closing conditions.

Jaded-Macaron-7574

 Iovance Biotherapeutics to Present at Upcoming Conferences SAN CARLOS, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences: TD Cowen’s 44th Annual Health Care Conference Fireside Chat: March 4, 2024 at 11:10 a.m. ET Boston, MA Barclays 26th Annual Global Healthcare Conference Fireside Chat: March 12, 2024 at 10:45 a.m. ET Miami, FL H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference Fireside Chat: March 26, 2024 at 1:30 p.m. ET Virtual The live and archived webcasts will be available at [https://ir.iovance.com/news-events/events-presentations](https://ir.iovance.com/news-events/events-presentations).

GoodGooglyMooglyy

You’re right, both have them. They’re called SAN (Schwab Advisor Network) and WAS (Wealth Advisor Solutions). Both have in-house managed solutions. They only use outside RIAs for things they can’t do in house like option strategies, private equity, DSTs, opportunity zone funds, to name a few

trainwreck001

Supermicro Announces Participation in Upcoming Investor Events 02/15/24 4:05 PM SAN JOSE, Calif.--(BUSINESS WIRE)-- Super Micro Computer, Inc. (Nasdaq: SMCI), a Total IT Solution Provider for AI, Cloud, Storage and 5G/Edge, today announced its participation in the upcoming investor conferences: Event: Morgan Stanley Technology, Media & Telecom Conference Date: March 4, 2024 Location: San Francisco, CA SMCI $4K 

YoupanicIdont

SAN and IEP do or did used to pay in shares. I would avoid either company like the plague. I don't understand why you are specifically looking for this, there is no strategic advantage behind it.

stoked_7

I replied to the OP with a site that compares brokerages and you don't like it. Sorry facts don't suit you. Here are more facts that you can downvote. **Robinhood Financial currently supports the following assets:** U.S. exchange-listed stocks and ETFs Options contracts for U.S. Exchange-Listed Stocks and ETFs ADRs for over 650 globally-listed companies **Robinhood Financial currently doesn’t support the following assets:** Foreign-domiciled stocks Select OTC equities Preferred stocks Mutual funds Bonds and fixed-income trading Stocks that trade on foreign exchanges Closed-end funds Limited partnerships Royalty trusts Tracking stocks New York registry shares Units Chinese securities affected by the White House’s executive order from Nov. 12, 2020 All Spanish ADRs: FRRVY, ACSAY, AMADY, RDEIY, PRISY, GRFS, TEF, SAN, BBVA, GILKY

musicboxangel

It's AI... from paypal website: ​ SAN JOSE, Calif., Jan. 16, 2024 /[PRNewswire](http://www.prnewswire.com/)/ -- PayPal Holdings, Inc. (NASDAQ: PYPL) today announced it will provide an exclusive preview on January 25, 2024 at 9:30 am PT of the first innovations PayPal and Venmo are piloting and bringing to market this year. PayPal First Look is a keynote hosted by Alex Chriss, PayPal President and CEO.  "Twenty-five years ago, at the dawn of the internet, PayPal was created and e-commerce was born – fast forward through decades of innovation and unimaginable growth, PayPal is leading the way to provide safe, secure experiences to customers around the world," said Alex Chriss, President and CEO, PayPal. "I invite you to join us on January 25th to hear about the next chapter of PayPal and how we're going to ***revolutionize commerce again through AI-driven personalization*** for both consumers and merchants."  

lost_in_life_34

cisco, oracle and others increased their profits back in 1999, but it was paper profits. they sold a bunch of stuff on credit and those dot coms went bust and all that gear was sold off on ebay. they were selling enterprise EMC SAN's on ebay then

faintobjects

What do you mean now? I just glanced and got a rough estimate. Seems nearly the same? It’s 2024 now though. I saw people saying the same thing with $SAN. My pops and Unc dropped loads just to have it dip .5% and they have been stuck there for nearly 15 years. Idk how to trade man, I just gamble and it seems to work out… I think ZIM is a no go.

keithobambertman

> Also auto rollback isn't always successful even in the bios update you're describing. These are solved problems, is the point. What does your SAN do? redundant controllers, redundant power supplies. One might argue that cars are more important to have not lock up than disk storage devices...

LiberalAspergers

Regional banks. HMST would be my pick. If it doesnt go to zero, seems likely to double. SAN is another contender

kemar7856

Google was actually paying women more then men nobody was crying about that 🫠 https://www.nytimes.com/2019/03/04/technology/google-gender-pay-gap.html#:~:text=SAN%20FRANCISCO%20%E2%80%94%20When%20Google%20conducted,women%20for%20doing%20similar%20work.